Arcus Biosciences Announces New Employment Inducement Grants

8/24/22 4:05:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RCUS alert in real time by email

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new employees options to purchase a total of 49,600 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 24,800 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in January 2020 pursuant to the "inducement exception" under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b) and most recently, HIF-2alfa. For more information about Arcus Biosciences' clinical and pre-clinical programs, please visit www.arcusbio.com or follow us on Twitter.

Inducement PR

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20220824005189/en/

Get the next $RCUS alert in real time by email

Recent Analyst Ratings for

$RCUS

Date	Price Target	Rating	Analyst
10/21/2024	$20.00	Neutral	H.C. Wainwright
10/8/2024	$29.00	Overweight	Wells Fargo
11/18/2022	$33.00	Neutral	BofA Securities
10/11/2022	$40.00	Overweight	Morgan Stanley
11/19/2021	$42.00 → $53.00	Buy	Citigroup
11/19/2021	$48.00 → $60.00	Overweight	Barclays
11/18/2021	$68.00 → $100.00	Outperform	SVB Leerink
11/9/2021	$45.00 → $48.00	Overweight	Barclays

More analyst ratings

Arcus Biosciences Announces New Employment Inducement Grants

Chat with this insight

Recent Analyst Ratings for $RCUS

$RCUS SEC Filings

Arcus Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

Arcus Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

SEC Form 10-Q filed by Arcus Biosciences Inc.

$RCUS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Jarrett Jennifer covered exercise/tax liability with 12,670 shares, decreasing direct ownership by 6% to 190,394 units (SEC Form 4)

Chief Medical Officer Nuyten Dimitry Sa covered exercise/tax liability with 5,385 shares, decreasing direct ownership by 5% to 94,933 units (SEC Form 4)

Chief Accounting Officer Azoy Alexander sold $20,314 worth of shares (1,357 units at $14.97), decreasing direct ownership by 7% to 19,070 units (SEC Form 4)

$RCUS Leadership Updates

Live Leadership Updates